PEG-MGFExplore study findings
What a withdrawn compounding nomination means
3 numbered sourcesSource years 2026
Short chains of amino acids connected by peptide bonds are peptides. Some interact with receptors, and a chemical modification can change how a peptide behaves. PEG-MGF refers to a synthetic MGF-related peptide joined to polyethylene glycol, or PEG. The FDA has tracked it separately from unmodified mechano growth factor. Its 2026 records illustrate the difference between a nomination to a compounding list and evidence supporting an approved drug. [1, 2]
A compounding nomination asks the agency to consider a bulk substance for a specific regulatory list. FDA’s record says the nominator withdrew the PEG-MGF nomination. The agency therefore removed the substance from Category 2 of its interim policy list. That category had identified nominated substances that might present significant safety risks. The record gives the procedural reason for the change, which is the withdrawal itself. It separately records FDA’s intention to seek advice about potential inclusion on the section 503A list. [1, 2]
FDA announced that it planned to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. An advisory meeting allows the committee to consider evidence and advise the agency. The announcement describes a planned discussion of a bulk ingredient, with a scope defined by the compounding question. FDA’s safety page continued to describe the human evidence gap for PEG-MGF after the nomination was withdrawn. [1, 2, 3]
This sequence shows why the date and reason next to a status change matter. The withdrawal documents what happened to one nomination. The committee notice documents a planned review. The safety record explains the evidence the agency had identified. Reading these records together preserves the distinctions between administrative history, the evidence base and a drug approval decision. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
